Sandbox

Do Not Delete

“	{	”
—- , a. LDL-C should be <100 mg/dL. (Level of Evidence: A)

---

Class III (No Benefit)

1. Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. (Level of Evidence: B)

2. Ongoing clinical screening is not indicated in genotype-negative relatives in families with HOCM. (Level of Evidence: B)

---

Class IIa

a. Reduction of LDL-C to <70 mg/dL is reasonable. (Level of Evidence:A)

b. If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. (Level of Evidence:B)

c. If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. (Level of Evidence:B)

d. Therapeutic options to reduce non HDL - C are Niacin (after LDL-C loweing therapy). (Level of Evidence:B)

e. Therapeutic options to reduce non HDL - C are Fibrate therapy (after LDL-C loweing therapy). (Level of Evidence:B)

---